Author: World Health Organization Publisher: World Health Organization ISBN: 9240081232 Category : Medical Languages : en Pages : 20
Book Description
Preterm birth (i.e. birth before 37 completed weeks of gestation) is the leading cause of neonatal mortality globally. There is an urgent need for new agents to prevent preterm birth, thereby reducing adverse outcomes for newborns. An initial target product profile (TPP) for drugs to prevent spontaneous preterm birth was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. The purpose of this TPP is to guide product developers and funders on the key characteristics and desired attributes of preventive agents that should be administered to pregnant women at increased risk of spontaneous preterm birth. This TPP outlines the minimal and preferred characteristics of a medicine that should: - reduce the likelihood of preterm birth and thus prevent (or mitigate) adverse newborn outcomes due to prematurity; - have an excellent safety profile during pregnancy; - be suitable for prescription or administration by skilled health personnel in any health care setting where pregnant women receive antenatal care, including in LMICs; - be commenced early in pregnancy and can be continued throughout pregnancy, as required.
Author: World Health Organization Publisher: World Health Organization ISBN: 9240081259 Category : Medical Languages : en Pages : 20
Book Description
Preterm birth (i.e. birth before 37 completed weeks of gestation) is the leading cause of neonatal mortality globally. Preterm newborns that survive are at an increased risk of a number of short- and long-term adverse health outcomes, including chronic lung disease, infections and neurological, visual and auditory disabilities. A number of tocolytic agents are currently in use internationally to slow down or stop the progression of labour. However, none of those has shown substantive improvements in fetal or newborn health outcomes.There is an urgent need for new agents to manage preterm birth, thereby reducing adverse outcomes for newborns. An initial target product profile (TPP) for drugs to manage preterm labour was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. The purpose of this TPP is to guide product developers and funders on the key characteristics and desired attributes of therapeutic agents for pregnant women experiencing spontaneous preterm labour.
Author: World Health Organization Publisher: World Health Organization ISBN: 9240081135 Category : Medical Languages : en Pages : 20
Book Description
TPP for drugs to prevent pre-eclampsia Pre-eclampsia and eclampsia affect 4.6% and 1.4% of pregnant women, respectively. They account for the majority of maternal deaths and stillbirths due to hypertensive disorders of pregnancy. Pre-eclampsia can also negatively affect fetal growth, and increase the risk of preterm birth and fetal death. There is an urgent need to identify new agents to prevent pre-eclampsia. An initial target product profile (TPP) for drugs to prevent pre-eclampsia was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. This WHO TPP describes the key characteristics and desired attributes of preventive agents that should be administered to pregnant women identified as being at increased risk of developing pre-eclampsia, accompanied by monitoring for the development of pre-eclampsia. This TPP outlines minimal and preferred characteristics of a medicine that should: - prevent the development of pre- eclampsia; - have a good safety profile during pregnancy; - be commenced early in pregnancy (before 20 weeks’ gestation) and continued throughout pregnancy and postpartum as required; - be suitable for administration in any health care setting where pregnant women receive antenatal care, including in LMICs.
Author: Agency for Healthcare Research and Quality/AHRQ Publisher: Government Printing Office ISBN: 1587634333 Category : Medical Languages : en Pages : 385
Book Description
This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 030910159X Category : Medical Languages : en Pages : 791
Book Description
The increasing prevalence of preterm birth in the United States is a complex public health problem that requires multifaceted solutions. Preterm birth is a cluster of problems with a set of overlapping factors of influence. Its causes may include individual-level behavioral and psychosocial factors, sociodemographic and neighborhood characteristics, environmental exposure, medical conditions, infertility treatments, and biological factors. Many of these factors co-occur, particularly in those who are socioeconomically disadvantaged or who are members of racial and ethnic minority groups. While advances in perinatal and neonatal care have improved survival for preterm infants, those infants who do survive have a greater risk than infants born at term for developmental disabilities, health problems, and poor growth. The birth of a preterm infant can also bring considerable emotional and economic costs to families and have implications for public-sector services, such as health insurance, educational, and other social support systems. Preterm Birth assesses the problem with respect to both its causes and outcomes. This book addresses the need for research involving clinical, basic, behavioral, and social science disciplines. By defining and addressing the health and economic consequences of premature birth, this book will be of particular interest to health care professionals, public health officials, policy makers, professional associations and clinical, basic, behavioral, and social science researchers.
Author: Hiroshi Sameshima Publisher: Springer Nature ISBN: 9811398755 Category : Medical Languages : en Pages : 252
Book Description
This splendid volume presents numerous aspects of preterm labor and delivery, from its fundamental mechanism to clinically focused approaches. The incidence of preterm delivery is 6-7% in Japan, while globally up to 10% of pregnancies with preterm labor result in premature delivery. The rates of overall survival and intact survival of the premature infants are also excellent in Japan. Thus Japan’s approach to preterm labor and delivery has long attracted attention. In each chapter, experts describe specific issues unique to conditions in Japan, including diagnosis, tocolytic agents, definition of clinical chorioamnionitis, treatment of bacterial vaginosis, role of amniocentesis, management of preterm premature membrane rupture and also placental pathology, presenting definitive evidence of the reduced incidence of preterm delivery in Japan. This book benefits not only obstetricians, pediatricians and gynecologist, but also midwives, nurse practitioners, and medical and associated staffs in the field of obstetrics, pediatrics, as well as neonatal and perinatal medicine who are involved in delivery.
Author: Peter C.K. Leung Publisher: Elsevier ISBN: 0323913814 Category : Science Languages : en Pages : 930
Book Description
Human Reproductive and Prenatal Genetics, Second Edition provides application-driven coverage of key topics in human reproductive and prenatal genetics, including genetic control underlying the development of the reproductive tracts and gametogenesis, the genetics of fertilization and implantation, the genetic basis of female and male infertility, as well as genetic and epigenetic aspects of assisted reproduction. Also examined are the genetics and epigenetics of the placenta in normal and abnormal pregnancy, preimplantation genetic diagnosis and screening, and cutting-edge advances in noninvasive prenatal screening, prenatal genetic counseling, and bioethical and medicolegal aspects of relevance in the lab and clinic. This new edition has been fully revised to address new and evolving technologies in human reproductive genetics, with new chapters added on chromatin landscapes and sex determination, genetic alterations of placental development and preeclampsia, metabolism and inflammation in PCOS, pre-implantational genetic testing, maternal genetic disorders, bioethics, and future applications. Features chapter contributions from leading international scientists and clinicians Provides in-depth coverage of key topics in human reproductive and prenatal genetics, including genetic controls, fertilization, placental development, embryo implantation, in vitro culture of the human embryo for the study of post-implantation development, and more Identifies how researchers and clinicians can implement the latest genetic, epigenetic, and –omics-based approaches Includes all new chapters on evolving technologies and recent genetic discoveries of relevance to reproductive medicine
Author: Jane Paul Publisher: International Labour Organization ISBN: 9221152383 Category : Technology & Engineering Languages : en Pages : 125
Book Description
Improving maternal health and reducing child mortality are among the eight UN Millennium Development Goals. This publication contains guidance on maternity protection in the workplace, focusing on measures that can be taken to establish a decent workplace and to identify workplace risks. The starting point is the Maternity Protection Convention (No. 183), adopted by the International Labour Conference in 2000 and its accompanying Recommendation (No. 191). The guide is intended for general use as a reference tool for employers, workers, trade union leaders, occupation health and safety advisors, labour inspectors and others involved in workplace health and maternity protection.
Author: United States. Public Health Service. Office of the Surgeon General Publisher: ISBN: Category : Government publications Languages : en Pages : 728
Book Description
This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.
Author: World Health Organization
Author: World Health Organization
Author: World Health Organization
Author: Agency for Healthcare Research and Quality/AHRQ
Author: Institute of Medicine
Author: Hiroshi Sameshima
Author: 
Author: Peter C.K. Leung
Author: Jane Paul
Author: United States. Public Health Service. Office of the Surgeon General